Amira El Tawdy

Cairo University, Cairo, Muhafazat al Qahirah, Egypt

Are you Amira El Tawdy?

Claim your profile

Publications (5)6.43 Total impact

  • Dermatologic Surgery 05/2013; 39(5):791-4. · 1.87 Impact Factor
  • Amira El Tawdy, Laila Rashed
    [Show abstract] [Hide abstract]
    ABSTRACT: Lichen planus (LP) is an inflammatory disease of the skin and oral mucosa. The association of LP and chronic hepatitis C virus (HCV) is well established, with variable prevalence rates among different populations. Toll-like receptors (TLRs) are key regulators of both the innate response and the adaptive response. However, TLRs also interact with endogenous ligands released by necrotic cells, and this process can intensify autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. To investigate the role of Toll-like receptor-7 (TLR-7) in LP through the detection of TLR-7 protein, and to compare between the expression of TLR-7 protein in HCV-positive and HCV-negative patients with LP. The study included 20 skin biopsies from patients with LP and 10 control biopsies. TLR-7 protein was detected by Western blot analysis. Detection of HCV-specific antibodies in the patient serum was done using ELISA technique. Our analysis revealed a significantly lower level of TLR-7 protein in all the LP skin biopsies compared with controls. The expression showed no difference between HCV-positive and HCV-negative patients. We concluded that TLR-7 abnormal expression in LP may have an impact on the pathogenesis of the disease. TLR-7 receptor and HCV relationship in patients with LP could not be confirmed by this study.
    International journal of dermatology 07/2012; 51(7):785-9. · 1.18 Impact Factor
  • Amira M. El Tawdy, Laila M. Rashed, Hadeel M. Alhanafy
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Atopic dermatitis is a highly pruritic, chronic inflammatory skin disease. There is no doubt that there is an epidermal barrier defect in atopic dermatitis. Some recent studies have found a correlation between epidermal barrier function and tight junction. Recently a correlation between tight and gap junction was also reported. Objective: To study the expression of connexin 43(Cx43) mRNA, an important constituent of gap junction in the skin in atopic dermatitis lesions and to compare it with healthy controls. Patients and methods: The study was carried out in 20 patients with atopic dermatitis. Fifteen healthy volunteers served as controls. A 4-mm punch skin biopsy specimen was obtained from each patient and control for quantitative reverse transcription-PCR measurement of Cx43 mRNA expression. Biopsy specimens were stored at −70°C. Reverse transcription-PCR was conducted using the extracted RNA for the detection of the Cx43 gene. Results: The mean Cx43 mRNA expression in the patients was 1.23±0.1 mg/gm tissue and 0.27±0.05 mg/gm in the control group. This denoted a significant statistical difference between the groups (P value=0.000) revealing higher expression in patients with atopic dermatitis. Conclusion: This study suggests a new hypothesis for atopic dermatitis pathogenesis showing a possible contribution of gap junction abnormality in the disease. These findings raise new future directions for management of patients with atopic dermatitis.
    Journal of the Egyptian Women’s Dermatologic Society. 06/2011; 8(2):78–83.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Percutaneous collagen induction (PCI) promotes removal of damaged collagen and induces more collagen immediately under the epidermis. The chemical reconstruction of skin scars (CROSS) method is a focal application of full-concentration trichloroacetic acid (TCA) to atrophic acne scars. The CROSS method has the advantage of reconstructing acne scars by increasing dermal thickening and collagen production. To compare the safety and efficacy of PCI and the 100% TCA CROSS method for the treatment of atrophic acne scars. Thirty participants were randomly equally divided into two groups; group 1 underwent four sessions (4 weeks apart) of PCI, and group 2 underwent four sessions (4 weeks apart) of 100% TCA CROSS. Acne scarring improved in 100% of patients. Scar severity scores improved by a mean of 68.3% (p<.001) in group 1 and a mean of 75.3% (p<.001) in group 2. The difference in the degree of improvement was not statistically significant between the groups (p=.47). PCI and 100% TCA CROSS were effective in the treatment of atrophic acne scars.
    Dermatologic Surgery 02/2011; 37(2):207-16. · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoralen ultraviolet A (PUVA) is a widely used first-line therapy for treatment of early cutaneous T-cell lymphoma. Narrow band UVB (UVB-NB) (311 nm) has been recently introduced as another effective line of treatment. It is postulated that the efficacy of UVB-NB could be enhanced by addition of psoralen. The aim of the present work was to compare the clinical and histopathologic efficacy of PUVA and UVB-NB in the treatment of early-stage MF (stages IA, IB and IIA), and to evaluate whether psoralen adds to the efficacy of UVB-NB or not. Patients and Methods: Twenty patients (stage IA, IB or IIA) were divided into two equal groups: group I received UVB-NB on the right body half vs. PUVA on the left side of the body for 48 sessions, and group II received PUVB-NB on the right side of the body vs. PUVA on the left side for 36 sessions. The sessions were administered three times weekly. In group I, almost equal results were obtained on both sides, i.e., UVB-NB and PUVA were equally effective in the treatment of early stages of MF, both clinically and histopathologically. In group II, PUVB-NB was found to be as effective as conventional PUVA in the treatment of early-stage mycosis fungoides, also on both clinical and histopathological grounds. UVB-NB phototherapy should be included among the initial therapeutic options of mycosis fungoides in view of its efficacy, convenience, and likelihood of fewer long-term adverse effects. Addition of psoralen does not seem to enhance its therapeutic efficacy.
    Photodermatology Photoimmunology and Photomedicine 01/2006; 21(6):281-6. · 1.52 Impact Factor